Novo Nordisk A/S (NVO) Analyst Ratings & Price Targets

Novo Nordisk A/S

NVO · NYSE

Analyst Consensus

Underperform

13 analysts

$40

Current

—

Low

$42

Average

—

High

Average target implies +4.92% versus the current price.

Analyst Ratings Synthesis

The supplied weekly consensus is Underperform across 13 analysts, with a mean target of $42.20; low and high targets are unavailable. Other supplied snapshots differ: StockAnalysis reports 14 analysts at Hold with a $44.89 average target, ChartMill reports 35 analysts and a $46.38 average, and MarketBeat lists a $59.44 target. These provider figures should not be combined into one target range. The evidence does not identify the most or least bullish analyst, nor does it report rating or target revisions during the week. The visible disagreement is limited to differing provider-level target and consensus snapshots; no named analyst thesis or firm-specific revision is supplied.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Morgan Stanley	—	Underweight Downgraded	—	—	Sep 10, 2026	Open the report this row came from
Morgan Stanley	—	Sell Downgraded	—	—	Sep 10, 2026	Open the report this row came from
Weiss Ratings	—	Hold Upgraded from Sell (D+) to Hold (C-)	—	—	Aug 5, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

CANTOR FITZGERA

EXANE BNP PARIB

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

Novo is the global healthcare company that believes lasting health starts now. For over a century, we've combined leading scientific expertise with a deep understanding of people's lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we're working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives.

Key Issues

Bullish view

Novo plans to expand its lineup and pipeline by 2030, with the aim of serving far more patients.

Bearish view

Lilly reported a Q3 earnings and sales beat driven by Mounjaro and Zepbound and raised its 2026 revenue outlook to $91-$92 billion, underscoring a strong competitor in obesity and diabetes medicines.

Analyst Consensus

See all

Underperform

13 analysts

$40

Current

—

Low

$42

Average

—

High

Average target implies +4.92% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Pfizer, Inc.PFE · NYSE